Joanne Lager

Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study

Claire Harrison, Nicolaas Schaap, Alessandro M. Vannucchi et al. · The Lancet Haematology · 2017 · 330 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +5

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

Michael Friedländer, Kenneth C. Hancock, Danny Rischin et al. · Gynecologic Oncology · 2010 · 226 citations

Medicine, Oncology, Pharmacology +15

Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models

C. Hotz, Timothy R. Wagenaar, Friederike Gieseke et al. · Science Translational Medicine · 2021 · 206 citations

Medicine, Immunology, Oncology +17

Phase I Study of 506U78 Administered on a Consecutive 5-Day Schedule in Children and Adults With Refractory Hematologic Malignancies

Joanne Kurtzberg, T J Ernst, Michael J. Keating et al. · Journal of Clinical Oncology · 2005 · 175 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A Phase I Study of the Pharmacokinetic and Safety Profiles of Oral Pazopanib With a High-Fat or Low-Fat Meal in Patients With Advanced Solid Tumors

Elisabeth I. Heath, E. Gabriela Chiorean, Christopher J. Sweeney et al. · Clinical Pharmacology & Therapeutics · 2010 · 100 citations

Pharmacy, Pharmacokinetics, Pharmacology +14